Advertisement

International Urology and Nephrology

, Volume 51, Issue 7, pp 1261–1270 | Cite as

Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study

  • Hasan Koc
  • Hasan Hoser
  • Yalcin Akdag
  • Cemaliye Kendir
  • F. Fevzi ErsoyEmail author
Nephrology - Original Paper
  • 61 Downloads

Abstract

Objective

To evaluate monthly percentage changes of intact parathyroid hormone (iPTH) and other major bone marker levels in patients with secondary hyperparathyroidism (SHPT) undergoing hemodialysis (HD) and receiving paricalcitol.

Methods

A total of 493 (F/M 244/249) adult patients with SHPT who were undergoing HD in 22 HD units and receiving paricalcitol treatment, with iPTH > 300 mg/mL, adjusted serum levels of calcium (Ca) < 10.2 mg/dL, and serum levels of inorganic phosphorus (iP) < 6 mg/dL were included in this multi-center, national, prospective, observational study. Data regarding efficacy, safety, and adverse events of paricalcitol treatment were collected during a 12-month follow-up period through monthly visits along with serum iPTH, Ca, iP, alkaline phosphatase (ALP) and other required biochemistry tests as necessary. Mortality data until 6 months after the end of the study were also investigated.

Results

The mean age was 58.3 ± 15.8 years and the mean duration of HD was 6.2 ± 5.5 years, respectively. As of 12th month, mean iPTH values decreased from 646 ± 424 pg/mL to 473 ± 387 pg/mL (p < 0.001); no statistically significant changes were observed in Ca levels (p > 0.05). Serum ALP levels also significantly decreased (p = 0.001) and serum phosphorus levels significantly increased (p < 0.001) during the study observation period. Reasons for early terminations were being lost to follow-up (n = 119, 24.1%), hyperphosphatemia (iP > 6 mg/dL, n = 108, 21.9%), low iPTH levels (iPTH < 150 mg/dL, n = 97, 19.7%), and withdrawal of consent (n = 41, 8.3%). In total 32 patients (6.5%) were prematurely terminated the study with hypercalcemia (Ca > 10.2 mg/dL). 46.9% of those hypercalcemic patients had other anomalies with iP and iPTH levels along with hypercalcemia.

Conclusion

Paricalcitol treatment, resulted in successful iPTH control. In approximately 6.5% of the patients paricalcitol treatment was discontinued since Ca levels reached > 10.2 mg/dL in those patients. No unfavorable effects on serum phosphorus and Ca–phosphorus (Ca × P) product were observed.

Keywords

Paricalcitol Chronic kidney disease End-stage renal disease Hemodialysis Hyperparathyroidism 

Notes

Acknowledgements

The authors would like to thank to MONITOR CRO, Istanbul, Turkey (funded by AbbVie) for the statistical analysis and assistance in medical writing.

Funding

This study was funded by AbbVie.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Disclosures

This study was sponsored by AbbVie. AbbVie contributed to the study design, research, and interpretation of data, writing, reviewing, and approving the publication. The design, study conduct, and financial support for the Zemplar PMOS study (protocol number P12-314) were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. All authors received payments from AbbVie to participate in this study. In addition, F. Fevzi Ersoy has received speaker and/or consultancy fees from AbbVie, Sanofi, Abdi Ibrahim and Roche. Hasan Hoser, Hasan Koc, Yalcin Akdag and Cemaliye Kendir have not received speaker and/or consultancy fees from AbbVie or any other pharmaceutical companies. The authors would like to acknowledge the other participants of the P12-314 Study Team.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Daly C (2007) Is early chronic kidney disease an important risk factor for cardiovascular disease A background paper prepared for the UK consensus conference on early chronic kidney disease. Nephrol Dial Transplant 22(Suppl. 9):19–25Google Scholar
  2. 2.
    Perazella MA, Khan S (2006) Increased mortality in chronic kidney disease: a call to action. Am J Med Sci 331(3):150–153CrossRefGoogle Scholar
  3. 3.
    Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17(7):2034–2047 (Epub 2006 May 31) CrossRefGoogle Scholar
  4. 4.
    Hajhosseiny R, Khavandi K, Goldsmith DJ (2013) Cardiovascular disease in chronic kidney disease: untying the Gordian knot. Int J Clin Pract 67(1):14–31CrossRefGoogle Scholar
  5. 5.
    Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(Suppl 3):S112–S119CrossRefGoogle Scholar
  6. 6.
    Abe M, Okada K, Soma M (2013) Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients. 5(3):1002–1023.  https://doi.org/10.3390/nu5031002 CrossRefGoogle Scholar
  7. 7.
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218CrossRefGoogle Scholar
  8. 8.
    Bansal B, Bansal S, Mithal A, Kher V, Marwaha R (2012) Vitamin D deficiency in hemodialysis patients. Indian J Endocrinol Metab 16(2):270–273.  https://doi.org/10.4103/2230-8210.93749 CrossRefGoogle Scholar
  9. 9.
    Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16:1788–1793CrossRefGoogle Scholar
  10. 10.
    Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V et al (2010) Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 31:2253–2261CrossRefGoogle Scholar
  11. 11.
    Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B et al (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520–528CrossRefGoogle Scholar
  12. 12.
    Ogawa T, Kyono A, Sato M, Sugimoto H, Otsuka K, Nitta K (2012) Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients. Clin Exp Nephrol 16:779–785CrossRefGoogle Scholar
  13. 13.
    Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S (2012) Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 27(8):3270–3278CrossRefGoogle Scholar
  14. 14.
    Brancaccio D, Cozzolino M, Cannella G, Messa P, Bonomini M, Cancarini G et al (2011) Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood Purif 32:124–132CrossRefGoogle Scholar
  15. 15.
    Messa P, Cozzolino M, Brancaccio D, on behalf of the FARO Study Group et al (2015) Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. BMC Nephrol 16:11CrossRefGoogle Scholar
  16. 16.
    Vervloet MG, Twisk JWR (2009) Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data. Nephrol Dial Transplant 24:703–706.  https://doi.org/10.1093/ndt/gfn492 CrossRefGoogle Scholar
  17. 17.
    National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39(suppl 1):S1–S266Google Scholar
  18. 18.
    KDIGO (2017) Clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2017(7):1–59Google Scholar
  19. 19.
    Olaizola I, Caorsi H, Fajardo L, Ferreiro A, Campistrus N, Dolinsky D, Petraglia A, Ambrosoni P (2016) Effectiveness and safety of a 6-month treatment with paricalcitol in patients on hemodialysis with secondary hyperparathyroidism. J Bras Nefrol 38(3):302–312CrossRefGoogle Scholar
  20. 20.
    Giachelli CM (2003) Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14:S300–S304CrossRefGoogle Scholar
  21. 21.
    Giachelli CM (2004) Vascular calcification mechanisms. J Am Soc Nephrol 15:2959–2964CrossRefGoogle Scholar
  22. 22.
    Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X et al (2007) Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18:2116–2124CrossRefGoogle Scholar
  23. 23.
    Silver J, Rodriguez M, Slatopolsky E (2012) FGF23 and PTH-double agents at the heart of CKD. Nephrol Dial Transplant 27:1715–1720CrossRefGoogle Scholar
  24. 24.
    Llach F, Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38:S45–S50CrossRefGoogle Scholar
  25. 25.
    Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D (2013) Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant 28(9):2260–2268CrossRefGoogle Scholar
  26. 26.
    Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM (2014) A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol 9(9):1620–1626CrossRefGoogle Scholar
  27. 27.
    Regidor DL, Kovesdy CP, Mehrotra R et al (2008) Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19(11):2193–2203CrossRefGoogle Scholar
  28. 28.
    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349(5):446–456CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Hayat Dialysis CenterIstanbulTurkey
  2. 2.Cinar Dialysis CenterKutahyaTurkey
  3. 3.Larende Dialysis CenterKaramanTurkey
  4. 4.Besyuzevler Safak HospitalIstanbulTurkey
  5. 5.Division of Nephrology, Department of Medicine, Akdeniz University Medical SchoolAkdeniz University HospitalAntalyaTurkey

Personalised recommendations